Also listed under Urinary Bladder Diseases
ClinicalTrials.gov term: Urinary Bladder Neoplasms
96 trials changed in the last 30 days: 2 stopped, 41 with notable changes, 53 with minor changes only.
Trial terminated
Also in this update: Final enrollment: 3 participants — 3% of the 120 planned; Primary completion date changed from estimate of Sep 1, 2027 to Jan 30, 2026
SystImmune Inc.Phase 1 NCT06714617 Registry history of NCT06714617 on ClinicalTrials.gov (opens the registry)
Trial status changed: Recruiting → Withdrawn
Case Comprehensive Cancer CenterPhase 2 NCT06290687 Registry history of NCT06290687 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 2026 to Jan 2027
BicycleTx LimitedPhase 1/2 NCT04561362 Registry history of NCT04561362 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 30, 2026 to Jul 30, 2027
National Cancer Institute (NCI)Phase 1 NCT02496208 Registry history of NCT02496208 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Feb 1, 2027 to Oct 14, 2028
Also in this update: Study completion pushed from Feb 1, 2029 to Oct 14, 2030
Alliance for Clinical Trials in OncologyPhase 2 NCT03609216 Registry history of NCT03609216 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 25, 2027 to May 29, 2028
City of Hope Medical CenterNot applicable NCT05519878 Registry history of NCT05519878 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 2026 to Oct 2027
Also in this update: Primary endpoint(s) modified; Enrollment increased: 400 → 450 participants
UroGen Pharma Ltd.Not specified NCT05874921 Registry history of NCT05874921 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
National Cancer Institute (NCI)Phase 2 NCT02465060 Registry history of NCT02465060 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Oct 3, 2026 to Oct 3, 2027
Also in this update: Study completion pushed from Apr 3, 2027 to Apr 3, 2028
Zhujiang HospitalPhase 2 NCT04861584 Registry history of NCT04861584 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 2026 to Dec 2027
Also in this update: Study completion pushed from Dec 2027 to Dec 2028
University Health Network, TorontoPhase 3 NCT04574960 Registry history of NCT04574960 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Enrollment increased: 202 → 228 participants; Trial sites expanded: 18 → 22 locations
Astellas Pharma Korea, Inc.Not specified NCT06011954 Registry history of NCT06011954 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 1, 2026 to May 1, 2028
Also in this update: Study completion pushed from May 1, 2027 to May 1, 2029
Zhujiang HospitalPhase 1/2 NCT06341400 Registry history of NCT06341400 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Dec 31, 2027
Also in this update: Study completion pushed from Dec 31, 2026 to Dec 31, 2028
Mayo ClinicPhase 1/2 NCT06704191 Registry history of NCT06704191 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jun 2027 to Dec 31, 2028
Also in this update: Interventions modified
Cancer Research UKPhase 1/2 NCT05944237 Registry history of NCT05944237 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to Jul 31, 2027
Yuanquan YangPhase 2 NCT06263153 Registry history of NCT06263153 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 2026 to May 2027
Fox Chase Cancer CenterPhase 2 NCT04506554 Registry history of NCT04506554 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 3 → 4
Eli Lilly and CompanyPhase 1 NCT06465069 Registry history of NCT06465069 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 30, 2025 to Aug 30, 2027
Also in this update: Trial status changed: Unknown → Recruiting; Study completion pushed from Sep 30, 2025 to Sep 30, 2028
Zhujiang HospitalNot applicable NCT03108196 Registry history of NCT03108196 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 1, 2025 to Dec 1, 2028
Also in this update: Study completion pushed from Dec 1, 2026 to Jul 1, 2029
Zhujiang HospitalNot applicable NCT05067101 Registry history of NCT05067101 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 1, 2025 to Dec 1, 2028
Also in this update: Trial status changed: Unknown → Recruiting; Study completion pushed from Jun 1, 2025 to Jun 1, 2029; and 1 more change in the last 30 days
Zhujiang HospitalNot specified NCT05558111 Registry history of NCT05558111 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Jul 30, 2027 to Aug 5, 2026
Prokarium LtdPhase 1 NCT06181266 Registry history of NCT06181266 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Harbin Medical UniversityPhase 2 NCT07624201 Registry history of NCT07624201 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 31, 2026 to Dec 31, 2026
BicycleTx LimitedPhase 1/2 NCT04180371 Registry history of NCT04180371 on ClinicalTrials.gov (opens the registry)
Trial completed
Toray Industries, IncPhase 1 NCT03872947 Registry history of NCT03872947 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 31, 2026 to Jan 1, 2027
National Cancer Institute (NCI)Phase 3 NCT03244384 Registry history of NCT03244384 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion pushed from Aug 15, 2026 to Aug 6, 2027; Primary completion date changed from estimate of Jun 15, 2026 to Aug 7, 2026
Avacta Life Sciences LtdPhase 1 NCT04969835 Registry history of NCT04969835 on ClinicalTrials.gov (opens the registry)
Trial completed
Cedars-Sinai Medical CenterNot specified NCT03193528 Registry history of NCT03193528 on ClinicalTrials.gov (opens the registry)
Trial completed
Nazmy Edward SeifNot applicable NCT06307704 Registry history of NCT06307704 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
Also in this update: Enrollment increased: 115 → 160 participants; Study completion pushed from Dec 30, 2026 to Dec 30, 2028
Medicenna Therapeutics, Inc.Phase 1/2 NCT05086692 Registry history of NCT05086692 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 27 participants (planned 23)
Memorial Sloan Kettering Cancer CenterPhase 2 NCT05239624 Registry history of NCT05239624 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Aug 2026 to Jan 26, 2026; Final enrollment: 7 participants (planned 9)
University of UtahPhase 1 NCT05154994 Registry history of NCT05154994 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 230 → 285 participants
Also in this update: Interventions modified; Trial arms changed: 3 → 2; and 1 more change in the last 30 days
Tyra Biosciences, IncPhase 2 NCT07265947 Registry history of NCT07265947 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Apr 14, 2026
M.D. Anderson Cancer CenterPhase 1 NCT00479128 Registry history of NCT00479128 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 285 → 330 participants
ModeX Therapeutics, An OPKO Health CompanyPhase 1/2 NCT06239194 Registry history of NCT06239194 on ClinicalTrials.gov (opens the registry)
Trial completed
NYU Langone HealthPhase 2 NCT02621151 Registry history of NCT02621151 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Mar 2027 to Sep 22, 2026
Memorial Sloan Kettering Cancer CenterPhase 2 NCT03093922 Registry history of NCT03093922 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 2026 to Nov 2026
Nazmy Edward SeifNot applicable NCT06408597 Registry history of NCT06408597 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 19 → 26 locations
And 1 more change in the last 30 days
Astellas Pharma Global Development, Inc.Phase 3 NCT07566156 Registry history of NCT07566156 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 104 → 107 locations
And 1 more change in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07419295 Registry history of NCT07419295 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Tianjin Medical University Second HospitalNot applicable NCT07180212 Registry history of NCT07180212 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 48 → 64 locations
And 1 more change in the last 30 days
Astellas Pharma Global Development, Inc.Phase 2 NCT07475806 Registry history of NCT07475806 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 2027 to Dec 2027
University of Michigan Rogel Cancer CenterNot applicable NCT07630155 Registry history of NCT07630155 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 111 → 114 locations
And 1 more change in the last 30 days
Ferring PharmaceuticalsPhase 3 NCT06510374 Registry history of NCT06510374 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 19 → 27 locations
Avenzo Therapeutics, Inc.Phase 1/2 NCT07038343 Registry history of NCT07038343 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to May 1, 2027
Mayo ClinicPhase 2 NCT06265285 Registry history of NCT06265285 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 18, 2026 to May 15, 2027
Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 1, 2027 to Jan 31, 2028
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1 NCT07140315 Registry history of NCT07140315 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 284 → 276 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 3 NCT07218380 Registry history of NCT07218380 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 76 → 80 locations
Ferring PharmaceuticalsPhase 3 NCT06545955 Registry history of NCT06545955 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 173 → 184 locations
And 1 more change in the last 30 days
PfizerPhase 1/2 NCT07421700 Registry history of NCT07421700 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 91 → 94 locations
Daiichi SankyoPhase 2 NCT06172478 Registry history of NCT06172478 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 2 → 47 locations
Paradigm HealthNot specified NCT06605404 Registry history of NCT06605404 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 31, 2026 to Aug 27, 2027
BeiGenePhase 1 NCT06257264 Registry history of NCT06257264 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 142 → 145 locations
National Cancer Institute (NCI)Phase 2 NCT06770582 Registry history of NCT06770582 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 165 → 177 locations
National Cancer Institute (NCI)Phase 2 NCT07061964 Registry history of NCT07061964 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 31, 2026 to Nov 30, 2027
Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Nov 30, 2025
Klus Pharma Inc.Phase 1/2 NCT04152499 Registry history of NCT04152499 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 31, 2026 to Dec 31, 2027
Janssen Research & Development, LLCPhase 3 NCT03390504 Registry history of NCT03390504 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 18 → 23 locations
Alliance for Clinical Trials in OncologyNot applicable NCT07059884 Registry history of NCT07059884 on ClinicalTrials.gov (opens the registry)
Interventions modified
Tyra Biosciences, IncPhase 2 NCT06995677 Registry history of NCT06995677 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Sep 6, 2026 to Jun 23, 2026
Jonsson Comprehensive Cancer CenterPhase 1 NCT07118176 Registry history of NCT07118176 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 2, 2026 to Sep 1, 2027
City of Hope Medical CenterPhase 1 NCT02432963 Registry history of NCT02432963 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jan 30, 2026 to Nov 30, 2026
AstraZenecaPhase 1 NCT02546661 Registry history of NCT02546661 on ClinicalTrials.gov (opens the registry)
Interventions modified
ExelixisPhase 1 NCT05176483 Registry history of NCT05176483 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Dec 23, 2026 to Apr 15, 2026
USWM CT, LLCPhase 1 NCT04044859 Registry history of NCT04044859 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 9, 2029 to Jun 28, 2030
Janssen Research & Development, LLCNot specified NCT07309445 Registry history of NCT07309445 on ClinicalTrials.gov (opens the registry)
Interventions modified
Washington University School of MedicinePhase 1 NCT06529822 Registry history of NCT06529822 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jun 2026 to Feb 2028
Also in this update: Primary completion date changed from estimate of Jun 2026 to Aug 30, 2025
University College CorkNot applicable NCT05946993 Registry history of NCT05946993 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Aug 2023); last known: Not Yet Recruiting
Power Life Sciences Inc.Not specified NCT06009510 Registry history of NCT06009510 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCSPhase 2 NCT05203913 Registry history of NCT05203913 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since May 2023); last known: Recruiting
Centre Hospitalier Universitaire de NīmesPhase 2 NCT04617756 Registry history of NCT04617756 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Apr 2024); last known: Not Yet Recruiting
Fondazione IRCCS Policlinico San Matteo di PaviaNot applicable NCT06355518 Registry history of NCT06355518 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCSNot specified NCT05878964 Registry history of NCT05878964 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Ludwig-Maximilians - University of MunichNot specified NCT05153694 Registry history of NCT05153694 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-19 | NCT07881666 Phase I Study of Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG… | Hopec Pharma new | Phase 1 |
| 2026-10-06 | NCT07860398 Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial… | Optheras AS new | |
| 2026-10-02 | NCT07855926 Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) | LMU Klinikum new | |
| 2026-09-11 | NCT07815665 A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in… | Summit Therapeutics new | Phase 2/3 |
| 2026-09-08 | NCT07808216 Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk… | Tianjin First Central Hospital new | Phase 2 |
| 2026-08-28 | NCT07793318 TR115 in ARID1A-Mutated Advanced Solid Tumors | Tarapeutics Science Inc. new | Phase 2 |
| 2026-08-25 | NCT07784387 A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in… | Janssen-Cilag Farmaceutica Ltda. new | |
| 2026-08-24 | NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… | Lumina Pharmaceuticals Inc new | Early Phase 1 |
| 2026-08-24 | NCT07781956 Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion… | Nanjing First Hospital, Nanjing Medical University new | |
| 2026-08-24 | NCT07782164 Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) | Amsterdam UMC, location VUmc new |
| Early Phase 1 | 15 | |
| Phase 1 | 113 | |
| Phase 1/2 | 86 | |
| Phase 2 | 217 | |
| Phase 2/3 | 15 | |
| Phase 3 | 88 | |
| Phase 4 | 11 |
National Cancer Institute (NCI) (36) · Memorial Sloan Kettering Cancer Center (20) · Peking University First Hospital (18) · M.D. Anderson Cancer Center (17) · AstraZeneca (15) · Merck Sharp & Dohme LLC (14) · Mayo Clinic (13) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (12) · Janssen Research & Development, LLC (11) · Tianjin Medical University Second Hospital (11)